Pharmacogenetic Determinants of Gefitinib Trough Concentration in Patients with Non-Small Cell Lung Cancer.
Shuang Xin,Yuxiang Ma,Xueding Wang,Yan Huang,Jiali Li,YuanYuan Zhao,Lingyan Chen,Rang Hu,Min Huang,Li Zhang
DOI: https://doi.org/10.1200/jco.2014.32.15_suppl.e13533
IF: 45.3
2014-01-01
Journal of Clinical Oncology
Abstract:e13533 Background: Some studies postulated that the plasma concentration of gefitinib may have great influence on its efficacy; meanwhile, it is well-known that polymorphisms in metabolic enzymes and transporters had great impact on drug exposure, which could partially account for interindividual variability of gefitinib clearance in the pharmacokinetic model. Therefore, this research investigated the association between genetic polymorphisms in CYP2D6, CYP3A4, CYP3A5, CYP1A1, POR, AHR, PXR, HNF4A and gefitinib trough concentration in patients with advanced non-small cell lung cancer (NSCLC). Methods: A total of 18 single nucleotide polymorphisms in CYP2D6 (rs1065852, rs5030656, rs1135840, rs28371725, rs16947), CYP3A4 (rs2242480), CYP3A5 (rs776746), CYP1A1 (rs762551, rs2606345, rs1048943), CYP1A2 (rs2069514), POR (rs2868177, rs121912974, rs17685), AHR (rs10249788, rs10248420, rs1169294), PXR (rs3814055) was selected and determined by Sequenom Massarray MALDI-TOF platform to analyze their association with the trough concentration of gefitinib in 81 NSCLC patients. Gefitinib trough concentration was detected on day 28 following first administration with HPLC-MS/MS. Mann-Whitney test and Kruskal-Wallis test were adopted to compare the distribution of gefitinib trough concentration between different genotype groups. Results: The trough concentration of gefitinib in CYP2D6 rs1135840 GG carriers was significantly higher than that in GC carriers plus CC carriers [223.31±74.76 vs 176.78±87.54 vs 164.36±131.27 (ng/mL), P<0.05]. CYP2D6 rs1065852 CT carriers had a higher gefitinib trough concentration than CC carriers [233.71±99.11 vs 149.28±74.02 (ng/mL), P<0.05]. Carriers of the CYP3A4 rs2242480 TT genotype had a significantly higher trough concentration than carriers of CT plus CC genotypes [314.77±66.72 vs 188.41±100.20 vs 186.72±91.18 (ng/mL), P<0.05]. Conclusions: This research demonstrated that the CYP2D6 rs1065852, CYP2D6 rs1135840 , CYP3A4 rs2242480 are associated with gefitinib concentration in NSCLC patients. A pharmacokinetic model incorporating the indicator of these polymorphisms may have potential for optimization of treatment with gefitinib.